SOURCE: YaFarm Technologies, Inc.

February 19, 2013 07:30 ET

YaFarm Technologies, Inc. Recaps Major Developments

PITTSTON, ME--(Marketwire - Feb 19, 2013) - YaFarm Technologies, Inc. (PINKSHEETS: YFRM) (YaFarm, or the Company) has reached several important milestones since signing the definitive agreement with The Integrative Stem Cell Institute (ISCI). YaFarm has appointed top level management for ISCI by announcing David Audley as CEO and Juan A. Castillo as Chairman of the Board of Directors. Dr. Castillo is a pioneer in regenerative medicine and has successfully treated over 250 patients using adult stem cells, while Mr. Audley successfully managed the International Cellular Medicine Society (ICMS) for nearly 4 years. Under Mr. Audley's leadership, the organization grew from 7 physicians to over 3500 members from 35 countries.

As a result of these appointments, ICSI has secured a definitive agreement with the Hospital Galenia in Cancun, Mexico to provide stem cell treatments at the medical center. Galenia is a state of the art medical facility with a staff of highly trained and globally respected medical professionals. ISCI has begun construction of a class 10,000, ISO 7 clean room for the processing of autologous, mesenchymal cells for point-of-care therapies. The ISCI lab is housed in the Hospital Galenia in Cancun, Mexico. ISCI believes that the design and construction of this category of laboratory space within a hospital setting is critical for the continued advancement of the field of regenerative medicine. In addition, ISCI has launched The International Stem Cell Practice (ISCP) to connect physicians with opportunities for education, training and collaboration in regenerative medicine, as well as international patients. Members of ISCP will work directly with ISCI in providing medical oversight and care to patients participating in clinical studies.

Last week YaFarm announced that the ISCI has submitted its complete protocols for the treatment of chronic and degenerative diseases to the Institutional Review Board (IRB) of the International Cell Surgical Society (ICSS). The IRB will study ISCI's procedures, while also reviewing the study. The studies ISCI submitted for approval will be conducted in its medical facility at the Hospital Galenia in Cancun, Mexico.

David Audley, CEO of the ISCI, said, "The ISCI has pioneered the field of cell-based regenerative medicine. We are excited about the potential for our world-class medical facility and state-of-the-art laboratory." Mr. Audley continued, "Through the ISCP, we plan to educate physicians about the field of regenerative medicine, while providing opportunities at the ISCI."

YaFarm Technologies CEO Brian Hermenze stated, "The progress we have made since signing the definitive agreement with the ICSI has put us ahead of schedule. Now we have a seasoned and successful management team in place, plans for a state of the art facility, and a network of physicians who can refer patients for procedures."

About The Integrative Stem Cell Institute (ISCI)
The Integrative Stem Cell Institute (ISCI) is a premier provider of point-of-care, stem cell-based therapies for patients from around the world. With a state of the art laboratory housed within the Hospital Galenia in Cancun, Mexico, the ISCI combines the most advanced scientific application of stem cells with second to none medical care within the structure of adaptive clinical trials to effective track long term outcomes and assure patient safety. More information on the Integrative Stem Cell Institute is available at


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition, adequate financing, and other material risks. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance, or achievements to be materially different from the statements made herein.

Contact Information

  • Contact:

    The Integrative Stem Cell Institute
    Contact: Miranda Abrahams

    Investor Contact
    Atlanta Capital Partners, LLC
    David Kugelman
    (866) 692-6847